Shares of BioMarin Pharmaceutical Inc. (BMRN) are trading at a roughly 39% discount to their 52-week high of $94.85, reached in August 2024, hovering around the $58 mark.
This global biotechnology company, developing targeted therapies that address the root cause of genetic conditions, has eight commercial therapies and a strong clinical and preclinical pipeline. Earlier this month, it expanded its late-stage pipeline through the acquisition of Inozyme Pharma Inc. (INZY). The acquisition brought in INZ-701, an enzyme replacement therapy currently in phase III development for ENPP1 Deficiency, a rare, serious, and progressive genetic condition that affects blood vessels, soft tissues, and bones. Data from the first phase III pivotal study of INZ-701 in children is expected in early 2026, with potential regulatory approval in 2027.
For comments and feedback: editorial@rttnews.com